Welcome to NovoCare® for Patient Affordability and Access Support
We understand how important it is to take the right medicine at a price you can afford, but it’s not always that easy. NovoCare® provides resources to help you understand your options, find costs, and connect you to affordability support.
Welcome to NovoCare® for Patient Affordability and Access Support
We understand how important it is to take the right medicine at a price you can afford, but it’s not always that easy. NovoCare® provides resources to help you understand your options, find costs, and connect you to affordability support.
Need assistance with insulin costs now?
In these challenging times, care is more important than ever. At Novo Nordisk, we’re helping to ensure your diabetes care continues without interruption.
We’re working hard to keep our medicines available and affordable for people like you who rely on them. If you need help paying for your insulin or other diabetes medicines, we can help.
Have you lost insurance coverage due to COVID-19? See how we can help
Our commitment during the global coronavirus outbreak
Novo Nordisk remains committed to supporting our patients during this difficult time. All NovoCare® patient support programs, including co-pay cards and assistance programs, remain available.
We’ve modified our Patient Assistance Program (PAP) to help those facing job loss, termination of health care benefits, or COBRA extension due to the pandemic. If you’re experiencing these economic hardships, you may be eligible to receive Novo Nordisk insulin free of charge for at least 90 days.
To help our patients access and afford their medications, NovoCare® continues to operate normally. This site is available 24/7 and we offer live support through the following phone numbers, Monday-Friday, 8:00am-8:00pm Eastern Standard Time:
- Diabetes: 844-Novo4Me (844-668-6463)
- Obesity: 888-809-3942
- Growth Hormone: 888-668-6444
- Hemophilia: 844-668-6732
In addition to addressing affordability concerns, we’re working to safeguard the continued supply of our life-saving medicines to patients. At present, we do not foresee a disruption in our ability to supply the US market with our medicines, including insulin. We have an inventory policy that helps ensure long-term supply. This is important since our medicines are needed every day by patients all over the world.
Fiasp®, Levemir®, Norditropin®, NovoCare®, NovoLog®, Ozempic®, RYBELSUS®, Saxenda®, Tresiba®, Victoza®, and Xultophy® are registered trademarks and Macrilen™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
© 2020 Novo Nordisk All rights reserved. US20NC00029 April 2020